57. A method of preventing, treating or ameliorating a bacterial infection, disease or condition in a subject, comprising administering to the subject an immunologically effective amount of an immunogenic composition of any one of claims 48 to 56.

58. The method of claim 57, wherein the infection, disease or condition is associated with *S. pneumonia* bacteria and the glycoconjugate comprises a capsular polysaccharide selected from the group consisting of Pn-serotype 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F capsular polysaccharides.

59. The method of claim 57, wherein the infection, disease or condition is associated with *N. meningitidis* bacteria and the glycoconjugate comprises a capsular polysaccharide selected from the group consisting of serotype A, C, W135 and Y capsular polysaccharides.

60. A method of inducing a protective immune response in a subject, comprising administering to the subject an immunologically effective amount of an immunogenic composition of any one of claims 48 to 56.

61. The method of claim 60, wherein the bacterial capsular polysaccharide is a capsular polysaccharide selected from the group consisting of Pn-serotype 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F capsular polysaccharides.

62. The method of claim 60, wherein the bacterial capsular polysaccharide is a capsular polysaccharide selected from the group consisting of serotype A, C, W135 and Y capsular polysaccharides.

57. An immunologically effective amount of an immunogenic composition of any one of claims 48 to 56 for use in preventing, treating or ameliorating a bacterial infection, disease or condition in a subject.

58. The use of claim 57, wherein the infection, disease or condition is associated with *S. pneumonia* bacteria and the glycoconjugate comprises a capsular polysaccharide selected from the group consisting of Pn-serotype 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F capsular polysaccharides.

59. The use of claim 57, wherein the infection, disease or condition is associated with *N. meningitidis* bacteria and the glycoconjugate comprises a capsular polysaccharide selected from the group consisting of serotype A, C, W135 and Y capsular polysaccharides.

60. An immunologically effective amount of an immunogenic composition of any one of claims 48 to 56 for use in inducing a protective immune response in a subject.

61. The use of claim 60, wherein the bacterial capsular polysaccharide is a capsular polysaccharide selected from the group consisting of Pn-serotype 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F capsular polysaccharides.

62. The use of claim 60, wherein the bacterial capsular polysaccharide is a capsular polysaccharide selected from the group consisting of serotype A, C, W135 and Y capsular polysaccharides.